GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives
Open accessThe DOI matches its Crossref record; 176 of the 178 references it cites were found in a registry or an index; 38 of the 156 sources its claims cite were checked for support.
Abstract
To date, non-alcoholic fatty liver disease (NAFLD) is the most frequent liver disease, affecting up to 70% of patients with diabetes. Currently, there are no specific drugs available for its treatment. Beyond their anti-hyperglycemic effect and the surprising role of cardio- and nephroprotection, GLP-1 receptor agonists (GLP-1 RAs) have shown a significant impact on body weight and clinical, biochemical and histological markers of fatty liver and fibrosis in patients with NAFLD. Therefore, GLP-1 RAs could be a weapon for the treatment of both diabetes mellitus and NAFLD. The aim of this review is to summarize the evidence currently available on the role of GLP-1 RAs in the treatment of NAFLD and to hypothesize potential future scenarios.
Overview
CoChat Summary
TL;DR
This narrative review summarizes evidence that GLP-1 receptor agonists improve weight, liver enzymes, steatosis, and steatohepatitis in NAFLD/NASH, with some signals for reduced fibrosis progression. It concludes that long-term human trials are still needed, especially for pre-existing fibrosis and HCC outcomes.
Key findings
- NAFLD is described as the most frequent liver disease, with a global estimated prevalence of 32.4% and affecting up to 70% of patients with diabetes; no specific drug treatment is currently available.
- GLP-1 RAs reduce body weight by about 1.5–6 kg or 2–7 kg depending on agent/dose, lower HbA1c by 0.8–1.9%, and are associated with a 9–16% reduction in cardiovascular events and all-cause mortality.
- In NASH trials, liraglutide achieved histological resolution of steatohepatitis in 39% vs 9% with placebo and reduced fibrosis progression (9% vs 36%, p = 0.04); semaglutide 0.4 mg/day achieved NASH resolution in 59% vs 17% with placebo and fibrosis progression in 5% vs 19%.
- Semaglutide 2.4 mg/week produced mean weight loss of 15.8% vs 6.4% with liraglutide in STEP 8, with >10% weight loss in 70.9% vs 25.6%, respectively.
Methods
- Narrative review of currently available evidence on GLP-1 RAs in NAFLD, including clinical trials, meta-analyses, observational data, and preclinical studies.
- The authors synthesize effects on body weight, hepatic cytolysis, steatosis, fibrosis, inflammation, and potential mechanisms, and discuss future dual/triple agonist perspectives.
- No systematic search strategy, formal quality assessment, or meta-analysis is described in the text.
Limitations
- The paper states that long-term trials evaluating GLP-1 RAs for reducing liver fibrosis are not currently available, and most fibrosis data come from indirect markers such as APRI, NFS, FIB-4, or liver stiffness.
- The paper states it is unknown whether benefits are direct or mediated by drug-induced weight loss, and several mechanistic hypotheses require further investigation.
- Evident from the text: this is a narrative review without a described systematic search or risk-of-bias assessment, and it relies on heterogeneous studies, including preclinical models and post hoc analyses.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
25 Valid · 3 Not valid · 81 Not checked · 13 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“In fact, if GIP receptor agonists (GIP RA) are effective in stimulating insulin secretion and favoring peripheral glucose uptake, alone they are unable to influence body weight [17,163].”
§ GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives > 5. Future Perspectives
What the sources say
- Disputedcites [17] Gallwitz, 2022, The incretin/glucagon system as a target for pharmacotherapy of obesity, Obes. Rev. sourceExperimental — accuracy not yet measured
The Conclusions section of our copy states the opposite of the attributed claim: 'GIPR agonism alone has been shown to reduce bodyweight in mice with obesity, as observed with GIPR agonists with a longer half-life than endogenous GIP,' adding only that 'these agents alone may have limited efficacy.' The GIP IN OBESITY section likewise reports 'a reduction in calorie intake and bodyweight after both central and peripheral administration of GIPR agonists,' while noting the role of GIP in obesity 'remains controversial' and that GIP has no acute effect on food intake in humans. The only passage supporting a null effect is narrower — DUAL GLP-1R/GIPR AGONISTS refers to 'GIP analogues that do not alter bodyweight when administered alone to mice with diet-induced obesity' — so the flat claim that GIP receptor agonists alone cannot influence body weight is contrary to what this source says; its insulinotropic action, the sentence's other half, is confirmed (GIP IN OBESITY). (LLM, conf=0.78)
Checked by a reasoning model — may be wrong.
- Not checked yetcites [163] Finan, 2013, Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans, Sci. Transl. Med. source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
Every source the paper cites for this claim was checked and supports it.
In the paper
“Since GLP-1 RAs are able to reduce appetite and induce satiety and early post-prandial fullness, their use is associated with a significant weight loss secondary to a reduced caloric intake [24].”
§ GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives > 2. GLP-1 Receptor Agonists: Mechanisms of Action and Current Indications
What the sources say
- Supportedcites [24] Nauck, 2021, GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art, Mol. Metab. source
The 'Weight loss induced by GLP-1 RAs' section states that GLP-1/GLP-1 RA administration 'reduces appetite and prospective food consumption, increases satiety and a feeling of abdominal fullness, and limits caloric intake under conditions of ad libitum feeding' and that 'All GLP-1 RAs after longer-term treatment lead to weight loss'. The adjacent mechanism table (Table 3) adds explicitly that 'Reduced caloric intake is the main mechanism leading to weight loss with GLP-1 RAs', and the text quantifies the effect as 'robust', usually 2-7 kg in type 2 diabetes. The paraphrase therefore matches the source on all elements: appetite reduction, satiety/fullness, weight loss, and caloric-intake reduction as the mediating mechanism. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In particular, at a dosage of 2.4 mg per week, it has been shown to induce an average weight loss between 9.6% and 17.4%, as well as a reduction in waist circumference and arterial hypertension and an improvement of lipid profile [34,35,36,37,39].”
§ GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives > 3. Effects of GLP-1 Receptor Agonists on NAFLD > 3.1. Effects of GLP-1 RAs on Body Weight
What the sources say
- Partly supportedcites [34] Wilding, 2021, Once-Weekly Semaglutide in Adults with Overweight or Obesity, N. Engl. J. Med. sourceExperimental — accuracy not yet measured
STEP 1 (our copy) reports a single mean weight change at 2.4 mg once weekly, not the 9.6–17.4% range the citing sentence attributes to its cluster of references: Change in Body Weight gives −14.9% (treatment-policy estimand) and −16.9% (trial-product estimand) versus −2.4% with placebo, and the Abstract/Discussion state the headline 14.9% mean loss. That value falls inside the quoted interval, so this source supports the dose-and-weight-loss point but supplies no lower bound of 9.6% or upper bound of 17.4% — those figures evidently come from the other trials in the citation cluster. The accompanying cardiometabolic points are backed here: Other Confirmatory and Supportive Secondary End Points report waist circumference −13.54 cm vs −4.13 cm, greater systolic/diastolic blood-pressure reductions, and favourable fasting lipid changes, and the Discussion lists reductions in waist circumference, blood pressure and lipid levels. (LLM, conf=0.75)
- Not checked yetcites [35] Davies, 2021, STEP 2 Study Group. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): A randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial, Lancet source
- Partly supportedcites [36] Wadden, 2021, Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial, JAMA sourceExperimental — accuracy not yet measured
In the Co-Primary End Points section our copy reports a single trial result, not a range: at week 68 mean weight change was -16.0% with semaglutide 2.4 mg/wk vs -5.7% with placebo (Abstract likewise gives -16.0%), and -17.6% vs -5.0% for the trial product estimand. So this source supports semaglutide 2.4 mg/wk inducing a large mean weight loss at the top of the cited interval (its trial-product estimate, -17.6%, actually slightly exceeds the claimed 17.4% upper bound), but it does not establish the 9.6%-17.4% range itself — nothing in our copy gives a 9.6% figure, which must come from the other pooled trials cited alongside it ([34,35,36,37,39]). The accompanying cardiometabolic points are supported: the Discussion/Supportive Secondary End Points report greater improvements in waist circumference, diastolic blood pressure and several lipid parameters vs placebo, while noting systolic blood pressure changed similarly in both groups and participants were not selected for elevated risk factors. (LLM, conf=0.78)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Notably, in the recent STEP 8 randomized clinical trial [46], semaglutide (2.4 mg/week) achieved a mean weight loss of 15.8% after 68 weeks of treatment compared with 6.4% obtained with liraglutide.”
§ GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives > 3. Effects of GLP-1 Receptor Agonists on NAFLD > 3.1. Effects of GLP-1 RAs on Body Weight
What the sources say
- Supportedcites [46] Rubino, 2022, Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial, JAMA source
The Primary Outcome section (p. ~4) states that at week 68 the estimated mean change in body weight was -15.8% with semaglutide and -6.4% with liraglutide, and the Abstract's Results report the same figures (-15.8% vs -6.4%; difference, -9.4 percentage points; P < .001). The Introduction/Abstract confirms the regimens compared were once-weekly subcutaneous semaglutide 2.4 mg vs once-daily liraglutide 3.0 mg over 68 weeks, matching every element of the claim. (LLM, conf=0.95)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Growing evidence supports the positive impact of GLP-1 RAs in reducing hepatic cytolysis enzymes [56,61,69,70,71,72,73,74,75,76,77,78,79,80,81] (Table 2).”
§ GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives > 3. Effects of GLP-1 Receptor Agonists on NAFLD > 3.2. Effects of GLP-1 RAs on Hepatic Cytolysis
What the sources say
- Supportedcites [56] Armstrong, 2016, Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): A multicentre, double-blind, randomised, placebo-controlled phase 2 study, Lancet source
The Introduction reports that GLP-1 analogues reduce liver enzymes in murine NASH models, and Evidence before this study reports improved liver enzymes with liraglutide in a meta-analysis of patients with type 2 diabetes. In this trial, the Results report a decrease in alanine aminotransferase over time, although the between-group difference at 48 weeks was not significant. (LLM, conf=0.90)
- Supportedcites [61] Newsome, 2021, A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis, N. Engl. J. Med. source
The Efficacy section (p. 7) reports dose-dependent reductions in liver-enzyme levels with semaglutide. The figure caption (p. 9) identifies the enzymes tracked as alanine aminotransferase and aspartate aminotransferase. This trial supports the cited claim for semaglutide in patients with NASH. (LLM, conf=0.93)
- Not checked yetcites [69] Buse, 2007, Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: An interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials, Clin. Ther. source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
67 more claims · 15 with their cited sources checked
Create a free account to see all 122 claims and to verify the 118 references still open.
- It may state two separate claims as one. 46
- Probably not a substantial claim. 6
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Thus, GLP-1 and its agonists slow down the progression of NASH and may positively impact the reversal of liver fibrosis.513,514”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [513]
The cited source says what the claim attributes to it.
In the citing paper
“Glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications improve health outcomes in patients with type 2 diabetes mellitus (T2DM).”
From Differences in GLP-1 RA medication adherence across place-based variables in patients with diabetes living in Wisconsin (2025) · cites this paper as [6]
The cited source says what the claim attributes to it.
In the citing paper
“Substantial evidence also supports the beneficial effects of the GLP-1 hormone on epicardial adipose tissue [48] and in the treatment of metabolic-associated fatty liver disease (MAFLD—formerly known as non-alcoholic fatty liver disease) [49].”
From New Developments in Pharmacological Treatment of Obesity and Type 2 Diabetes—Beyond and within GLP-1 Receptor Agonists (2024) · cites this paper as [49]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives > 3. Effects of GLP-1 Receptor Agonists on NAFLD > 3.1. Effects of GLP-1 RAs on Body Weight
“The dose used for the treatment of obesity (2.4 mg/week) is significantly more effective in determining weight loss than that used for the treatment of T2DM (1.0 mg/week) [35].”
§ GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives > 3. Effects of GLP-1 Receptor Agonists on NAFLD > 3.1. Effects of GLP-1 RAs on Body Weight
“The maximum dose of semaglutide used for the treatment of obesity is 2.8 mg/week (0.4 mg/day), whereas the maximum dose for the treatment of T2DM is 1 mg/week.”
Citations
Cites
1 retracted
Portillo-Sanchez, P., Bril, F., Maximos, M., Lomonaco, R., Biernacki, D., Orsak, B., Subbarayan, S., Webb, A., Hecht, J., & Cusi, K. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-2739 · Cited by 200
RetractedSemaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205 · cited 1×
“2021 Wilding [34] 1961 nondiabetic obese Prospective double-blind Semaglutide vs placebo Yes Semaglutide (2.”
BackgroundEASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.11.004 · Cited by 4,836
Eslam, M., Newsome, P. N., Sarin, S. K., Anstee, Q. M., Targher, G., Romero-Gomez, M., Zelber-Sagi, S., Wai-Sun Wong, V., Dufour, J.-F., Schattenberg, J. M., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.03.039 · Cited by 4,472
Autophagy regulates lipid metabolism
Singh, R., Kaushik, S., Wang, Y., Xiang, Y., Novak, I., Komatsu, M., Tanaka, K., Cuervo, A. M., & Czaja, M. J. (2009) · Nature · doi:10.1038/nature07976 · Cited by 3,975
Angulo, P., Kleiner, D. E., Dam-Larsen, S., Adams, L. A., Bjornsson, E. S., Charatcharoenwitthaya, P., Mills, P. R., Keach, J. C., Lafferty, H. D., Stahler, A., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.043 · Cited by 2,987
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
Vilar-Gomez, E., Martinez-Perez, Y., Calzadilla-Bertot, L., Torres-Gonzalez, A., Gra-Oramas, B., Gonzalez-Fabian, L., Friedman, S. L., Diago, M., & Romero-Gomez, M. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.005 · Cited by 2,492
Long-term follow-up of patients with NAFLD and elevated liver enzymes
Ekstedt, M., Franzén, L. E., Mathiesen, U. L., Thorelius, L., Holmqvist, M., Bodemar, G., & Kechagias, S. (2006) · Hepatology · doi:10.1002/hep.21327 · Cited by 2,302 · cited 1×
“Indeed, patients with NAFLD and elevation of liver cytolysis enzymes have an increased risk of NASH and progression to cirrhosis [63].”
Background
Cited by
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy
Zheng, Z., Zong, Y., Ma, Y., Tian, Y., Pang, Y., Zhang, C., & Gao, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01931-z · Cited by 1,036
“513,514 These signaling pathways suggest that GLP-1 and its receptor agonists may in fl uence the progression of NASH through multiple mechanisms, providing several potential therapeutic targets including: FOXO1, a transcription factor that plays a critical role in regulating glucose and lipid…”
BackgroundMetabolic dysfunction-associated steatotic liver disease in adults
Huang, D. Q., Wong, V. W. S., Rinella, M. E., Boursier, J., Lazarus, J. V., Yki-Järvinen, H., & Loomba, R. (2025) · Nature Reviews Disease Primers · doi:10.1038/s41572-025-00599-1 · Cited by 293
Emerging role of GLP-1 agonists in obesity: A comprehensive review of randomised controlled trials
Popoviciu, M.-S., Păduraru, L., Yahya, G., Metwally, K., & Cavalu, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241310449 · Cited by 280
Therapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH)
Do, A., Zahrawi, F., & Mehal, W. Z. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-01084-2 · Cited by 169
Tschöp, M., Nogueiras, R., & Ahrén, B. (2023) · Diabetologia · doi:10.1007/s00125-023-05929-0 · Cited by 92
“GLP-1 receptor agonists have also shown success in other therapeutic areas apart from type 2 diabetes and obesity, in particular for non-alcoholic fatty liver disease [104].”
Background
Metadata
- Authors
- Nevola, R., Epifani, R., Imbriani, S., Tortorella, G., Aprea, C., Galiero, R., Rinaldi, L., Marfella, R., & Sasso, F. C.
- Affiliations
- University of Campania "Luigi Vanvitelli" (IT)
- Corresponding author
- Sasso, Ferdinando Carlo
- ORCID
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2023-01-15
- Volume
- 24
- Issue
- 2
- Pages
- 1703
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC9865319
- OpenAlex
- W4316664733
- Cited by
- 286
- References
- 178
- Citations by year
- 2026: 77 · 2025: 108 · 2024: 75 · 2023: 26
- FWCI
- 11.13
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" (submittedVersion)
- Archivio Istituzionale della Ricerca - Università degli Studi del Molise (submittedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Keywords
- GLP-1 receptor agonists, non-alcoholic fatty liver disease, diabetes mellitus, liver fibrosis, weight loss, cardioprotection, renal protection, hypoglycemic effect, NAFLD treatment
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-1 Receptor Agonists, Diabetes Mellitus, Type 2, Humans, Liver, Glucagon-Like Peptide 1, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-04, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-04 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives. https://app.cochat.ai/papers/10.3390/ijms24021703
- The paper
- Nevola, R., Epifani, R., Imbriani, S., Tortorella, G., Aprea, C., Galiero, R., Rinaldi, L., Marfella, R., & Sasso, F. C. (2023). GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24021703
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.